As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

As­traZeneca’s ex­trav­a­gant pro­jec­tions for its clot fight­er Bril­in­ta may have fiz­zled in the face of un­der­whelm­ing tri­al da­ta — but a new piv­otal study is set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER